-
Aggressive Approach to Very Advanced Cancer Does Not Extend Survival
Study shows no benefit from treatment for cancers at very advanced stages of progression. Researchers urge end-of-life planning for these patients.
by Kyle Bagenstose
-
Support Grows for Making Transfusions a Part of Hospice
Blood cancer patients have low rates of enrollment in hospice. One barrier to enrollment is that many hospices do not provide blood transfusions.
by Jon Kelvey
-
Navigating Hospital Discharge Decisions
Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
-
Immunotherapy in the Elderly
Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
-
Starting a Conversation
Palliative care physician Dawn Gross helps people talk about death by focusing on what they want during life.
by Amy Paturel
-
Combining Treatment With Hospice Services
Organizations are testing new models of end-of-life care that allow patients to start hospice without stopping treatment.
by Cheryl Platzman Weinstock
Cancer Talk
Researchers Tackle Immune-related Adverse Effects
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin